THERAPEUTIC SLTNS INTL - TSOI STOCK NEWS

Therapeutic Solutions International's pre-spin-off company, Campbell Neurosciences, appoints Raymond Oliver as Chairman of the Board to facilitate its entry into the capital markets. The company plans to distribute up to 10,000,000 shares to existing shareholders in a loyalty dividend. Campbell Neurosciences is focused on developing innovative technologies for the treatment of psychiatric diseases and suicidal propensities.

Therapeutic Solutions International, Inc. (TSOI) announces the granting of a patent for QuadraMune® to stimulate natural killer (NK) cell activity in COVID-19 patients. The patent covers immune suppression inhibition, SARS-CoV-2 prevention, brain protection, and T regulatory cell upregulation. The Company aims to address medical needs through innovative therapies and nutraceuticals.

Therapeutic Solutions International, Inc. (TSOI) announces groundbreaking results in experiments showing the healing effects of JadiCells involve an interplay between immunological cells. The data suggests that JadiCells amplify therapeutic effects through monocytes and T cells expressing specific molecules, with potential applications in lung diseases like ARDS and COVID-19. The Company is progressing towards Phase III trials for COVID-19 and ARDS, aiming to revolutionize treatment standards.

Therapeutic Solutions International, Inc. (TSOI) reveals groundbreaking data showing enhanced gene therapy effects with JadiCell administration. The company demonstrated a significant increase in therapeutic cell production by combining gene therapy with JadiCell, particularly effective in treating hormone-producing cell deficiencies. Dr. Thomas Ichim and Timothy Dixon express optimism about the potential impact on clinical translation and seek collaborators for further development.

Therapeutic Solutions International, Inc. (TSOI) has filed a Civil Action in the Superior Court of the State of California to disclose the identities of individuals posting defamatory statements on StockTwits. The company seeks to enjoin further defamatory communications and recover from significant injuries. StockTwits, InvestorsHub, and Yahoo message boards are targeted for allowing users to post anonymously, potentially leading to fraud and stock market manipulation.

Therapeutic Solutions International, Inc. (TSOI) has formed Epilepsy Bio, Inc., a subsidiary company dedicated to commercializing intellectual property, clinical, and mechanistic findings associated with cellular and immunological approaches to epilepsy. The company successfully treated an advanced epilepsy patient using its patented JadiCell universal donor stem cell product and plans to change the standard of care for some subsets of epilepsy patients. The global epilepsy market size was valued at USD 2.61 billion in 2021 and expected to reach USD 4.70 billion by 2030.

Therapeutic Solutions International, Inc. (TSOI) successfully treated four advanced cancer patients with FloraStilbene™, a drug comprising the abortion pill's active ingredient and pterostilbene. No adverse events were observed, and clinical signals of tumor response were noted. The drug has shown efficacy in stimulating immune responses in animal models of various cancers, with emphasis on triple negative breast tumor models. The use of pterostilbene for cancer immunotherapy was patented by the company. The data from this treatment will serve as the basis for future clinical trials for FDA sales approval. The company has the support of leaders of the Pro-Life Movement. The rapid translation of FloraStilbene™ from a laboratory discovery to a compounded drug speaks volumes to the power of the company's team.

Therapeutic Solutions International, Inc. (TSOI) announced the formation of ALS Biologics Inc, a subsidiary company dedicated to accelerating development of assets related to Amyotrophic Lateral Sclerosis. The company aims to improve outcomes for ALS patients and eventually cure the disease by leveraging previous positive patient experiences with the ALScell™ (JadiCell™) product under the Right to Try Law. The company plans to file for IND for ALS treatment by the second quarter of 2024.

Therapeutic Solutions International, Inc. (TSOI) announced a publication with Campbell Neurosciences and academic institutions regarding the modulation of the indolamine 2,3 dioxygenase pathway in depression by QuadraMune®, a patented nutraceutical. The publication highlights the potential of QuadraMune® in treating major depressive disorder, addressing the 'Silent Epidemic' of depression resistant to conventional medication.